바로가기  >

Abstract

BACKGROUND AND PURPOSE:

To compare the plan quality of tri-(60)Co magnetic-resonance image-guided radiation therapy (IGRT) to that of volumetric modulated arc therapy (VMAT) for lung stereotactic ablative radiotherapy (SABR).

MATERIALS AND METHODS:

A total of 22 patients with lung tumors located in the lower lobe were selected retrospectively. For each patient, VMAT plans with linac and intensity-modulated radiation therapy (IMRT) plans with the tri-(60)Co system were generated with prescription doses of 60Gy (daily dose=15Gy). For both plan types, identical CT image sets and structures were used, with the exception of planning target volumes (PTV). The PTV for VMAT was generated from the internal target volume (ITV) while the PTV for the tri-(60)Co system was generated from the gross tumor volume (GTV). Clinically relevant dose-volumetric parameters were calculated and analyzed.

RESULTS:

The average PTV volumes of tri-(60)Co plans and VMAT plans were 10.5±12.3cc vs. 27.2±23.5cc, respectively (p<0.001). The maximum and mean doses to PTVs were 64.0±2.6Gy vs. 62.5±0.9Gy (p=0.005) and 61.4±1.7Gy vs. 60.0±0.5Gy (p<0.001), respectively. The conformity and homogeneity indices were 1.89±0.38 vs. 1.01±0.40 (p<0.001) and 0.06±0.02 vs. 0.04±0.00 (p<0.001), respectively. No considerable differences for organs at risk (OARs) were observed between tri-(60)Co plans and VMAT plans. In terms of target conformity, integral dose and lung mean dose, the plan quality of tri-(60)Co plans was inferior to that of VMAT plans when the PTV volumes of tri-(60)Co plans were less than 10cc. However, all treatment plans of tri-(60)Co system were clinically acceptable.

CONCLUSION:

For lung SABR, the quality of ITV-based VMAT plans was better than that of GTV-based tri-(60)Co plans especially when the PTV volumes of the tri-(60)Co plans were less than 10cc. If the breathing pattern of a patient is reproducible, VMAT is considered the optimal option for lung SABR, otherwise the tri-(60)Co IGRT should be considered due to the ability to monitor tumor motion during treatment. 

Author information

Park JM1, Park SY2, Kim HJ3, Wu HG3, Carlson J4, Kim JI5.​

1Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea; Center for Convergence Research on Robotics, Advanced Institutes of Convergence Technology, Suwon, Republic of Korea.

2Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.

3Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.

4Program in Biomedical Radiation Sciences, Department of Transdisciplinary Studies, Seoul National University Graduate School of Convergence Science and Technology, Seoul, Republic of Korea.

5Department of Radiation Oncology, Seoul National University Hospital, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea; Center for Convergence Research on Robotics, Advanced Institutes of Convergence Technology, Suwon, Republic of Korea. Electronic address: madangin@gmail.com.